Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Epidermolysis Bullosa Simplex

In brief

Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.

Key facts

Study ID
NCT03154333
Run by
Castle Creek Pharmaceuticals, LLC
People needed
54
Starts
2017-06-01
Expected to finish
2018-10-31
Last updated by the study team
2019-11-05

Who can join

Age: 4 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.